The diabetes drug empagliflozin (Jardiance) is now approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, even if they do not have diabetes.Nurses and NPs should monitor patients for adverse effects, especially fluid deficits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000833908.32698.29 | DOI Listing |
Publication Analysis
Top Keywords
diabetes drug
8
heart failure
8
drug approved
4
approved heart
4
failure diabetes
4
drug empagliflozin
4
empagliflozin jardiance
4
jardiance approved
4
approved reduce
4
reduce risk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!